Fecal microbiota transfer and inflammatory bowel disease: A therapy or risk?

Krista M. Newman, Carlos G. Moscoso, Byron P. Vaughn

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


Inflammatory bowel disease (IBD) results from the inappropriate stimulation of intestinal bacteria in a genetically susceptible host. IBD has a distinct microbiota pattern, although it is unclear if this is causal to inflammation or a result of ongoing inflammation. In addition to microbiota population differences, there are essential changes in the functions of the microbiota, which may result in chronic inflammation. Restoration of the intestinal microbiota may ameliorate inflammation. While there are multiple mechanisms of modulating the intestinal microbiota, fecal microbiota transplantation (FMT) has the potential to dramatically shift and restore the intestinal microbiota, and thus is a potential therapy for IBD. However, data to support efficacy in the IBD population remain limited. Additionally, optimization of donor selection, mode, route, and frequency of the fecal material remains under investigation. The challenge to identify long-term safety profiles, stable engraftment, and ideal bacterial populations remains but will provide the foundation for development of the next-generation FMT.

Original languageEnglish (US)
Title of host publicationMicrobiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications
Number of pages10
ISBN (Electronic)9780128152492
ISBN (Print)9780128152508
StatePublished - Jan 1 2019

Bibliographical note

Publisher Copyright:
© 2019 Elsevier Inc. All rights reserved.


  • Crohn’s disease
  • Dysbiosis
  • Fecal microbiota transplant
  • Inflammatory bowel disease
  • Microbiome
  • Ulcerative colitis


Dive into the research topics of 'Fecal microbiota transfer and inflammatory bowel disease: A therapy or risk?'. Together they form a unique fingerprint.

Cite this